Researchers with McMaster University have discovered that the protein mutated in patients with Huntington's Disease doesn't repair DNA as intended, impacting the ability of brain cells to heal ...
The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...